Werewolf Therapeutics, Inc. (HOWL)

In the past six months, Werewolf Therapeutics, Inc.'s stock price has been impacted by several events. The company provided promising clinical data updates for WTX-124 and WTX-330. Werewolf Therapeutics announced its board initiated a process to explore strategic alternatives to maximize stockholder value. The company reported its third-quarter 2025 and full-year 2025 financial results, with the full year net loss narrowing. Wall Street analysts maintained a largely bullish outlook with a median price target of $7.00, but the company has a consensus rating of "Hold". The stock has experienced volatility, with a 52-week range between $0.53 and $2.38.

As a biopharmaceutical company focused on research and development, Werewolf Therapeutics, Inc. does not currently have commercialized products, so there is no discernible demand seasonality. Demand will be driven by clinical trial outcomes, regulatory approvals, and market adoption.

Werewolf Therapeutics, Inc. is a biopharmaceutical company focused on developing therapeutics to stimulate the body's immune system for treating cancer and other immune-mediated conditions. The company uses its PREDATOR platform to engineer conditionally activated molecules, INDUKINE and INDUCER molecules, to stimulate adaptive and innate immunity. Its lead product candidates include WTX-124, an Interleukin-2 molecule for advanced or metastatic solid tumors, which has received Fast Track Designation for cutaneous melanoma, and WTX-330, an Interleukin-12 molecule for advanced or metastatic solid tumors and lymphoma. The company is also developing other candidates such as JZP898, WTX-921, WTX-712, WTX-518, WTX-1011, and WTX-2022.

Werewolf Therapeutics, Inc. is headquartered in Watertown, Massachusetts, United States, with its primary operations and market focus within the United States.

Werewolf Therapeutics' brand reputation has been influenced by its clinical development progress and strategic corporate decisions. Positive attention has been received for promising clinical data, regulatory milestones such as the FDA's Fast Track Designation for WTX-124, and the strategic review to explore alternatives. Analyst sentiment has been largely bullish, although the consensus rating is "Hold."

The ownership structure of Werewolf Therapeutics stock includes institutional, insider, and public/individual investors. Major institutional owners and shareholders include Ra Capital Management, L.p., Mpm Asset Management Llc, and Vanguard Group Inc. Peter Kolchinsky owns the most shares of Werewolf Therapeutics. Insiders have sold more company stock than they have bought in the past three months.